Literature DB >> 11113376

Diagnosis of defects in the type 1 cytokine pathway.

D A Lammas1, P Drysdale, A Ben-Smith, J Girdlestone, D Edgar, D S Kumararatne.   

Abstract

Patients with inherited defects in the interleukin-12 (IL-12)-dependent, 'high-output' interferon-gamma (IFN-gamma) pathway exhibit selective susceptibility to poorly pathogenic mycobacterial and salmonella infections. This review summarises the extended clinical spectrum seen in this group of patients and indicates a strategy for the identification of putative defects in the type 1 cytokine pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11113376     DOI: 10.1016/s1286-4579(00)01313-7

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  3 in total

Review 1.  Heterogeneity in the granulomatous response to mycobacterial infection in patients with defined genetic mutations in the interleukin 12-dependent interferon-gamma production pathway.

Authors:  David A Lammas; E De Heer; J D Edgar; V Novelli; A Ben-Smith; R Baretto; P Drysdale; J Binch; C MacLennan; D S Kumararatne; S Panchalingam; T H M Ottenhoff; J-L Casanova; J F Emile
Journal:  Int J Exp Pathol       Date:  2002-02       Impact factor: 1.925

2.  Acquired predisposition to mycobacterial disease due to autoantibodies to IFN-gamma.

Authors:  Beate Kampmann; Cheryl Hemingway; Alick Stephens; Robert Davidson; Anna Goodsall; Suzanne Anderson; Mark Nicol; Elisabeth Schölvinck; David Relman; Simon Waddell; Paul Langford; Brian Sheehan; Lynn Semple; Katalin A Wilkinson; Robert J Wilkinson; Stanley Ress; Martin Hibberd; Michael Levin
Journal:  J Clin Invest       Date:  2005-08-25       Impact factor: 14.808

3.  Adjuvant interferon gamma in patients with drug - resistant pulmonary tuberculosis: a pilot study.

Authors:  Roberto Suárez-Méndez; Idrian García-García; Norma Fernández-Olivera; Magalys Valdés-Quintana; María T Milanés-Virelles; Dalia Carbonell; Delfina Machado-Molina; Carmen M Valenzuela-Silva; Pedro A López-Saura
Journal:  BMC Infect Dis       Date:  2004-10-22       Impact factor: 3.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.